Colon cancer is a cancer of the digestive system that starts in the colon, which is part of the large intestine. Because it has many similarities to rectal cancer, the two cancers are often referred to as colorectal cancers. In most cases, colorectal cancers develop slowly over many years and are treatable if diagnosed early; regular screening for colon cancer is critical.

In 2007 (the most recent year for which statistics are available), 142,672 Americans were diagnosed with colorectal cancer, including 72,755 men and 69,917 women. Excluding skin cancers, colon cancer is the third-most-common cancer in the United States. Over 90 percent of cases occur after the age of 50.

The death rate from colon and rectal cancers has been declining for two decades because of the prevalence of screening and early prevention. The American Cancer Society recommends that people at average risk for colon cancer have a screening test (colonoscopy or other type) beginning at age 50. The five-year survival rate for colon cancer now stands at about 90 percent when the cancer is found and treated early.

The primary treatment for colon cancer is surgery, either through an abdominal incision or, increasingly, through laparoscopic surgery. Laparoscopic surgery uses several smaller incisions that heal faster and limit damage to the patient’s immune system. Depending on the stage at which the cancer is detected, radiation and chemotherapy may also be options for colon cancer treatment.


  1. Treatment standards at Bayonne Medical Center (BMC) exceeds national guideline metric:

According to the national quality metrics set forth by the American College of Surgeon (ACoS) Commission on Cancer (CoC) “Chemotherapy should be considered or administered within 120 days of diagnosis for patients under age 80 with stage III Colon Cancer”.

Bayonne Medical Center ensures this standard 100% of the time, compared to 80.1% at state level and 86% at national level.

2. Care at Bayonne Medical Center (BMC) consistent with national treatment guidelines established by the National Comprehensive Cancer Network (NCCN):

The National Comprehensive Cancer Network (NCCN) guideline states that testing for KRAS mutation should be performed /offered for Stage IV Colon cancer patient”.

KRAS mutation testing guides physicians in choosing particular chemotherapy agents, thus saving toxicities of ineffective treatment to the patients.)

A review of medical records for colon cancer patients treated at BMC between the year 2011 to 2014 shows that 100% of all eligible patients had KRAS testing performed, thus reflecting the excellence in care provided to colon cancer patient treated at BMC.

Contact information

  • Cancer Care at Bayonne Medical Center29 East 29th Street
    Bayonne NJ 07002
    Phone: 201.858.5364
  • Cancer Care at Christ Hospital176 Palisade Avenue
    Jersey City NJ 07306
    Phone: 201.795.8200
  • Cancer Care at Hoboken University Medical Center308 Willow Avenue
    Hoboken NJ 07030
    Phone: 201.418.1000